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von Willebrand disease (VWD) is a common autosomal-domi-
nant inherited bleeding disorder caused by quantitative or
qualitative defects of von Willebrand factor (VWF), a multi-
adhesive protein which binds platelets to exposed subendothe-
lium, participates inplatelet aggregation and carries factor VIII in
circulation. VWD is classiﬁed into six different types (►Table 1).
Type 1 and 3 VWD reﬂect the partial or complete quantitative
deﬁciency of VWF, respectively, while four type 2 variant reﬂect
different qualitative defects of VWF.1 Type 2 displays a wide
heterogeneity of functional abnormalities reﬂecting the location
of the causative mutations in the VWF protein.1
Among type 2 variants, VWD type 2B (VWD2B) is unique
because of its peculiar pathophysiology and laboratory
phenotype.2 This was ﬁrst shown by Ruggeri et al who
identiﬁed a group of VWD patients, now classiﬁed as type
VWD2B, with variable reduction of plasma VWF, but with
in vitro ristocetin-induced platelet agglutination (RIPA)
occurring at concentrations lower than those required for
normal controls and other patients with VWD.3 Subse-
quently, a lack of high-molecular-weight (HMW) multi-
mers of VWF in plasma was observed and attributed to a
heightened interaction of the abnormal VWF with the
physiological glycoprotein (Ib-α; GpIb-α) receptor on
platelet membrane.4 Furthermore, increasing plasma
concentration of this mutant protein by administering
desmopressin (DDAVP) could induce a variable degree of
thrombocytopenia, which was however, already present at
baseline in a signiﬁcant proportion of patients.5,6
VWD2B is a rare (3% of all VWD cases), usually highly
penetrant autosomally inherited bleeding disorder caused by
gain-of-function mutations in A1 domain of VWF.6 Around
50% of patients with this type exhibit mild-to-moderate
thrombocytopenia, which can be unraveled or further aggra-
vated by some clinical circumstances (e.g., surgery, infection,
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Abstract Type 2B von Willebrand disease (VWD2B) is a rare, autosomal-dominant inherited
bleeding disorder, characterized by an enhanced ristocetin-induced platelet aggrega-
tion in platelet-rich plasma and often with variable degree of thrombocytopenia and loss
of high-molecular-weight multimers vonWillebrand factor (VWF). All these phenomena
are caused by a mutant VWF, normally synthesized and assembled by endothelial cells,
but with heightened afﬁnity binding to the platelet receptor glycoprotein Ib-α (GpIb-α).
When this abnormal VWF is released into the circulation and under speciﬁc clinical
circumstances, in vivo platelet clumping is observed. Mutations, invariably clustered in
exon 28 of the VWF gene encoding for the VWF A1 domain involved in VWF binding to
GpIb-α, are responsible for VWD2B phenotype. Clinical and laboratory phenotype
appears strongly related to the type of VWF-causative mutations. However, recent
evidences suggest that a true platelet defect is also present in this type, with several
morphological and functional abnormalities being detected in a subset of VWD2B
patients.
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pregnancy), because of the increased release of the abnormal
VWF by the endothelial cells.6
Genetic Background and Heterogeneity of
Laboratory Phenotypes
Along with type 2A, VWD2B was the ﬁrst type of VWD for
which demonstration of speciﬁc causative VWFmutation has
been provided.7,8 The identiﬁcation of speciﬁc segments in
the A1 domain responsible for the interaction with platelet
GpIb-α receptor has led to investigating exon 28 of VWF gene,
which codes for A1 domain.7,8 Indeed, several mutations, all
clustered in exon 28 have been associated with VWD2B
(►Table 2) (also see, http://www.ragtimedesign.com/vwf/
mutation/), for most of them expression experiments have
clearly demonstrated the causative role of the amino acid
change. Most VWD2B mutations are missense, of which
R1306W, R1308C, V1316M, and R1341Q represent approxi-
mately 80 to 90% of the observed mutations.9 For some of
these mutations, there is a clear relationship with loss of
HMWmultimers and chronic thrombocytopenia while it has
been shown that P1266L mutation, previously reported as
type New York/Malmoe VWD,10,11 is invariably not associ-
ated with loss of HMW multimers and thrombocytopenia.6
How Type 2B VWF Inﬂuences Platelets
Patients with some mutations (e.g., I1309V, V1316M) are
particularly prone to develop thrombocytopenia at baseline
or after triggering clinical situations,6 while in others it does
not occur at all (e.g., P1266Q/L or 3923G>T R1308L). Throm-
bocytopenia inversely correlates with the increase of circu-
lating levels of conformational active form of type 2B VWF,
which may also interact spontaneously with GpIb-α6
Apart from affecting the interaction with GPIb-α, recent
ﬁndings suggest that 2B VWFmay also affect platelet produc-
tion. In addition to platelet aggregates, in peripheral blood
smears of VWD2B patients giant platelets may also be
evident.6,12 Of note, recently it has been shown that the
disorder previously called Montreal platelet syndrome, char-
acterized by thrombocytopenia with large platelets and
bleeding symptoms, is indeed caused by the V1316M VWF
mutation.13Megakaryocytes frompatientswith VWD2Bhave
an altered morphology and produce abnormal and fewer
platelets than normal controls, suggesting that the continu-
ous interaction with GpIb-α of abnormal VWF during mega-
karyocytes maturation inﬂuences the formation of platelets
in these patients.14 Recently, in a murine model for VWD2B,
which reproduces the phenotype observed in humanpatients
with the disorder, Casari et al found that murine VWD2B
platelets, again depending on the type of mutation, have a
variably shorter circulatory survival than wild-type platelets,
which could contribute to the lower platelet count in VWD2B
mice.15 This underlines the role of VWF-type 2B in inducing
the formation of abnormal platelets with shortened lifespan
in circulation. Importantly, further analysis revealed that
VWF-type 2B is exclusively present at the surface of platelets
of thrombocytopenic VWD2B mice, suggesting that VWF
binding to platelets is needed to induce thrombocytopenia.15
Table 1 Classiﬁcation of VWD
Quantitative deficiency of VWF
Type 1: Partial quantitative deﬁciency of VWF
Type 3: Virtually complete deﬁciency of VWF
Qualitative deﬁciency of VWF (variant VWD)
Type 2: Qualitative deﬁciency of VWF
Type 2A: Qualitative variants with decreased
platelet-dependent function associated with the
absence of high- and intermediate-molecular-weight
VWF multimers
Type 2B: Qualitative variants with increased afﬁnity
for platelet GPIb
Type 2M: Qualitative variants with decreased
platelet-dependent function not caused by the absence
of high-molecular-weight VWF multimers
Type 2N: Qualitative variants with markedly decreased
afﬁnity for factor VIII
Abbreviations: GpIb, glycoprotein Ib; VWD, von Willebrand disease;
VWF, von Willebrand factor.
Source: Modiﬁed from Sadler et al.1
Table 2 Mutations identiﬁed in exon 28 of VWF gene associated
with type 2B VWD phenotype
Nucleotide change Amino acid substitution
3797C > T or A P1266L/Q
3802C > A or G H1268N/D
3910A > G M1304V
3912insATG M1304insM
3916C > T R1306W
3917G > A R1306Q
3917G > T R1306L
3922C > T R1308C
3923G > C R1308P
3925A > G I1309V
3929C > T S1310F
3939G > C W1313C
3940G > C V1314L
3941T > A V1341D
3946G > A V1316M
4010C > T P1337L
4021C > T R1341W
4022G > A or C or T R1341Q/P/L
4115T > G I1372S
4378C > G L1460V
4382C > A or T A1461D/V
Abbreviation: VWD, von Willebrand disease.
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These VWF–platelet complexes are taken up efﬁciently by
macrophages in the liver and spleen, thus accelerating their
clearance.16,17 Interestingly, increase of circulating levels of
conformational active form of 2B VWF also promotes VWF
binding by macrophages. Macrophage depletion leads to a
two- to threefold increase of platelet counts in thrombocyto-
penic mice with type 2B V1316M mutation, characterized by
the most severe thrombocytopenia.15 Furthermore, it was
recently found that activation of VWF via exposure to shear
stress, enhances macrophage uptake, thus contributing
signiﬁcantly to the clearance of VWF.17
Thus, thrombocytopenia in VWD2B appears to be
the result of at least a combination of shortened survival of
the abnormal platelets and of an accelerated clearance of the
abnormal VWF/platelet complexes by macrophages in the
liver and spleen.18 VWD2B appears to not only be a disorder
of a plasma hemostatic protein, but also of platelets, suggest-
ing that, in addition to VWF/factor VIII concentrates, transfu-
sion of normal platelets may be justiﬁed in VWD2B patients
with bleeding and worsening of their thrombocytopenia due
to hemostatic stress situations.18
Furthermore, recent studies from the same group demon-
strated that also platelet dysfunction is present in VWD2B.19
A dysregulated platelet signaling upon binding to GpIb-α,
which severely impairs platelet aggregation, secretion and
platelet spreading was in fact demonstrated on the basis of a
decreased activation of the platelet ﬁbrinogen integrin
receptor αIIbβ3 as a consequence of type 2B VWF binding
to GpIb-α. This altered platelet function would of course add
to increase the risk of bleeding carried by low VWF with loss
of HMW multimers and thrombocytopenia.20
Proteolysis and Clearance of Type 2B Von
Willebrand Factor
Loss of HMW multimers in VWD2B is due to increased
ADAMTS13 (a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13) proteolysis.21
Furthermore, low-density lipoprotein receptor-related pro-
tein 1 (LRP1) plays a major role in shear-dependent macro-
phage-mediated clearance of VWF, and binds VWFexclusively
under conditions of elevated shear-stress forces.16,17,22 It has
been demonstrated that the VWF A1 domain contains an
interactive site for LRP1 and that the degree of this site
exposure is modulated by peculiar VWD2B mutations.23
Recent evidence has been provided to show that some
VWD2B mutations display shear-stress independent binding
to LRP1.23 Furthermore, in a mouse model macrophage-LRP1
contributes to increased clearance of R1306Q and V1316M in
vivo even without shear stress, explaining the increased
clearance of these type 2B mutations.23
Laboratory Diagnosis
A wide heterogeneity of laboratory phenotypes is evident in
VWD2B, being strictly associated with the causative
mutation. The hallmark unifying all the different types of
mutations, however, is the evidence of an heightened
response to low concentrations of ristocetin in the RIPA assay.
Usually, the laboratories screen for VWD2B by using a risto-
cetin concentration of 0.5 mg/mL and a response is deﬁned as
the concentration of ristocetin able to induce at least 30% of
the aggregation amplitude after 3 minutes from its addition
to patient’s platelet rich plasma. This occurs at higher doses
than 0.5 mg/mL with some mutations (e.g., P1266L) while at
lower doses (even 0.3mg/mL)with others (V1316M). Variable
reduction of plasma VWF antigen (VWF:Ag) and VWF risto-
cetin cofactor (VWF:RCo) is observed, but also normal levels
have been reported and VWF:RCo/VWF:Ag ratio may also be
normal, at variancewith type 2A and type 2M. Also, FVIII may
be normal or only slightly reduced. There is a tendency for
ﬂuctuating levels of both VWF:RCo and VWF:RCo/VWF:Ag
ratio according to the degree of ongoing type 2BVWF–platelet
interaction.6 Loss of HMW and sometimes intermediate-
molecular-weight multimers is typically present in patients
with the mutations more frequently associated with throm-
bocytopenia (V1316M, R1308C)6 while the proﬁle is normal
in patients with the previously deﬁned New York/Malmoe
subtype (P1266L).6,10,11 In keeping with the demonstrated
increased binding to speciﬁc LPR1 receptors, VWF propeptide
to VWF:Ag ratio is increased,22 which represents a sensitive
index of increased VWF clearance.24,25
VWD2B must be distinguished from a platelet disorder
expressing similar laboratory phenotype, named platelet-type
VWD (PT-VWD), inwhich gain-of-functionmutations in platelet
GpIb-α similarly cause loss of plasma HMW VWF multimers,
variable thrombocytopenia, and enhanced RIPA.26,27 Several
laboratory methods have been developed to discriminate
between the two disorders, including cryoprecipitate challenge
and simpliﬁed RIPA mixing assays,27 but only the identiﬁcation
of speciﬁc mutations in GP1BA gene will clarify the different
pathophysiology.28 In addition, recentevidences suggest that the
bleeding tendency is milder in PT-VWD patients.29
VWD2B should be always considered in the presence of
inherited chronic thrombocytopeniawith large platelets on
blood smear. This would also help to avoid misleading
therapeutic approaches, including corticosteroids and
splenectomy, as observed in the experience of the authors
(G.C. and A.B., data not shown). Furthermore, in those
patients with thrombocytopenia, family studies could
help showing the high consistency of platelet count abnor-
mality associated with the lifelong bleeding tendency.6
Clinical Management of VWD2B: Bleeding
Phenotype and Therapy
As for the other patients with signiﬁcantly low VWF, bleeding
tendency in VWD2B ismainly represented bymucocutaneous
bleeding. The severity and frequency of bleeding symptoms
and requirement of substitutive treatment is somewhat
similar to what is observed in type 2A and more severe
that typical type 2M and type 1. From a clinical point of
view, the risk of bleeding is approximately ﬁvefold higher in
VWD2B patients with associated thrombocytopenia below
140  103 platelets/µL compared with those with normal
platelet counts.6 However, wide variation again exists
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according to the responsible mutation and this means that
when enhanced RIPA is detected mutation detection is of
utmost importance in identifying the patients more at risk of
signiﬁcant bleeding (►Table 3). Recurrent gastrointestinal
bleeding associated with gastrointestinal angiodysplasia has
also been described.30 Pregnancy in VWD2B can cause or
worsen thrombocytopenia and platelet transfusions have
been used at parturition in some patients.31,32
VWF replacement therapy is usually required for VWD2B
patients, especially in those with the mutations at risk of
signiﬁcant bleeding and/or thrombocytopenia. Dose and tim-
ing of administration are similar to what is usually advised in
other VWD types requiring substitutive treatment.33 The goal
of treatment in patients undergoing major surgery is to
maintain FVIII and VWF (typically using VWF:RCo as
the laboratory parameter) plasma levels around 80 to
100 IU/dL for at least a couple of days and trough level above
50 IU/dL for an additional 5 to 7 days thereafter. A loading dose
of 50 IU/kg of VWF:RCo is usually given in severe cases 30
minutes to 1 hour before surgery, followed by similar daily
doses for the next 2 days. A single or daily doses for 2 to 3 days
of 20 to 60 IU/kg of VWF:RCo (depending on the severity of
bleeding) are hemostatically effective for treating spontaneous
bleeding episodes or for preventing bleeding during invasive
procedures. It should be kept in mind, however, that in some
situationswith ongoing bleeding there could be aworsening of
thrombocytopenia because of increased stimulation of the
release of the abnormal VWF from endothelial cells and blood
count, especially platelets, should be closely monitored.
In the past, there have been reports of possible clinical
effectiveness of DDAVP in a few cases of VWD2B patients,
without signiﬁcant thrombocytopenia34 and there is clear
evidence that some mutations (P1266L, R1308L) do not show
anyplatelet decrease afterDDAVPadministration.6However, the
compound should be used cautiously and probably best avoided
in patients already displaying thrombocytopenia at baseline or
with mutations known to be associated with possible aggrava-
tion of thrombocytopenia.
Alloantibodies to VWF are rare and reported to occur
mainly in type 3 patients in whom no VWF is synthesized
in association with homozygous null mutations, including
gene deletions.35 However, the occurrence of alloantibodies
to VWF in a patient with VWD2B (R1308C mutation) after
substitutive treatment has been recently reported.36 Inter-
estingly, the antibody speciﬁcity seems to be restricted
toward the active platelet-binding conformation of the A1
domain of VWF.36 Following this report, it appears that
closely monitored measurement of FVIII/VWF activities after
substitutive treatment is advised, especially after intensive
treatment in previously minimally treated patients.
Conclusions
VWD2B represents a rare, but fascinating bleeding disorder,
which displays awideheterogeneity of laboratory and clinical
phenotypes. The interaction of type 2B VWF and platelet
production and function is worthy of further studies to
elucidate this complex interaction. Identifying the responsi-
ble VWD2Bmutation appears relevant not only to distinguish
it from the PT-VWD, but also to predict the severity of
bleeding tendency and type of treatment.
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